Our annual survey highlights several academic startups developing immunotherapies as well as ventures focusing on microbiomes, proteostasis, integrin biology, nucleic acid delivery and subcellular imaging. Similarly to recent years, 2016 saw continued enthusiasm for investments in cuttingedge technology and early-stage products. In addition to traditional venture capital firms, corporate venture capital, non-profits and accelerators are now also contributing to seed funding. According to industry newsletter BioCentury, investments in life science companies by corporate venture arms continued to surge, accounting for 30% of startup financing last year.
VOLUME 35 NUMBER 4 APRIL 2017 NATURE BIOTECHNOLOGY
Para acessar a publicação na íntegra clique aqui